AfterRaise/Companies/Cyllene Therapeutics

Cyllene Therapeutics

€33M Series CRaised 3 months agoFranceBiotech & PharmaFrance

In their own words

What Cyllene Therapeutics says it is doing

Work here? Claim your company profile
Market expansionResearch and development

Public signal Read from the company's own description of what the funding supports.

Why now

Where Cyllene Therapeutics is today

Cyllene Therapeutics announced a Series C round of €33M on 7 July 2026.

Latest round
Series C
Amount
€33M
Announced
7 July 2026
Headquarters
France
Sector
Biotech & Pharma
Growth stage
Series C+
Investors
Not stated
Also participating
Andera Partners SAS, Bpifrance Investissement, InnoBio 3 Fund, L.P
Relevant leadership
CEO Philippe Chambon

Momentum AfterRaise intelligence

AfterRaise Score

54
Steady growth
0 funding signals in the last 90 days
Funding recency
18/40
announced within the last 6 months
Round scale
16/25
round size relative to the market
Funding stage
20/20
Series C
Funding cadence
0/15
one funding event tracked this year
Arriving with the signals layer
  • Hiring momentum Open roles and hiring pace
  • Market expansion New offices and new countries
  • Leadership Executive appointments
  • Product activity Launches and releases

Since the raise

What has happened since

  • 7 July 2026
    €33M Series C
    Investors not stated in the announcement.

Public signal The timeline currently holds funding events, because those are the signals AfterRaise observes today. Hiring, leadership, expansion and product events join it with the signals layer.

What may happen next

What this raise could create

AfterRaise intelligenceNot a statement of fact

What may happen next

  • New market entry
  • First local hires in the new market
  • Local entity and legal setup
  • Research programme expansion

Opportunities this could create

  • Clinical operations
  • Scientific hiring
  • Licensing and BD partnerships
  • Market-entry advisers
  • Local employment infrastructure

Based on the Biotech & Pharma sector, a Series C+ round and the priorities the company itself set out. Not a statement of fact.

Medium momentum3 connected signals
  • 7 July 2026€33M Series C announced
  • 7 July 2026Stated priority: market expansion
  • 7 July 2026Stated priority: research and development

High momentum means several meaningful company changes have occurred in a short period. Signals here are funding events and the priorities the company stated; hiring, leadership and expansion detection join with the signals layer.

Open to

What Cyllene Therapeutics is open to

Not yet specified

Cyllene Therapeutics has not told AfterRaise which approaches it welcomes. Until it does, we do not assume. Offers to help are held and shown to the company, and the company decides whether to open a conversation.

Work here? Set your preferences

Opportunities

Ways to work with Cyllene Therapeutics

No open opportunities listed

Jobs, projects, partnerships, advisory and supplier needs appear here once the company has claimed its page and published them, and any role we read from its own job board appears automatically.

Work here? Open the first one

Helpful contributors

People who have contributed here

Nobody yet

When someone offers help and the company says it was useful, they appear here. Reputation on AfterRaise is built from contributions the company confirmed, not from follower counts.

Do you work at Cyllene Therapeutics?

Claim your company profile.

This page was created from publicly available information. A verified representative corrects the record, says what the company is building next and chooses which conversations it welcomes.

What we do not have yet: your website and the roles and projects you have open. Claiming the page is how you fill those in.

Someone else requesting access does not give them ownership. Every representative is verified by a person before access is granted.

Maintaining your own company profile is free. A founder, CEO or authorised senior colleague can represent the company.

Also moving

Other Biotech & Pharma companies

See the sector